{"brief_title": "A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma", "brief_summary": "To evaluate tolerance, toxicity, and preliminary evidence of antitumor efficacy of intralesionally administered tumor necrosis factor (TNF) and to define a maximum tolerated dose (MTD) for single intralesional injections. In addition, to assess the effects of TNF injections on Kaposi's sarcoma (KS) lesions as measured by P-32 magnetic resonance spectroscopy.", "condition": ["Sarcoma, Kaposi", "HIV Infections"], "intervention_type": ["Drug"], "intervention_name": ["Tumor Necrosis Factor"], "criteria": "Inclusion Criteria Patients must have: - Biopsy-proven Kaposi's sarcoma (KS) with multiple cutaneous lesions. - Minimum life expectancy of 3 months. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Clinically significant cardiac disease. - Known hemorrhagic diathesis or active bleeding disorder. - Clinically apparent vascular disease. - Known lipoprotein disorders. - History of seizure disorder or central nervous system (CNS) metastasis. - Additional malignancy. Concurrent Medication: Excluded: - Cardiac agents. - Anticoagulants. - Thrombolytic agents. - Nonsteroidal anti-inflammatory drugs. - Corticosteroids. - Aspirin. - Vasodilators. Patients with the following are excluded: - Additional malignancies or other conditions listed in Patient Exclusion Co-Existing Conditions. Prior Treatment: Excluded within 4 weeks of study entry: - Chemotherapy. - Radiotherapy. - Immunotherapy.", "gender": "Male", "minimum_age": "18 Years", "maximum_age": "70 Years", "healthy_volunteers": "No", "keyword": "Acquired Immunodeficiency Syndrome", "mesh_term": ["HIV Infections", "Sarcoma", "Necrosis", "Sarcoma, Kaposi", "Skin Neoplasms"], "id": "NCT00002262"}